Perry Karsen - Director, Oncomed Pharmaceuticals Inc

As of June 25, 2018


What is Perry Karsen's Net Worth?

The current estimated net worth of Oncomed Pharmaceuticals Inc's Director, Perry Karsen, is estimated to be about $23.87M . Perry Karsen owns about 10,000 units of Oncomed Pharmaceuticals Inc common stock. In the last year at Oncomed Pharmaceuticals Inc, Perry Karsen has sold an estimated value of $0 worth.

What is Perry Karsen's Past Insider Trading?

Perry Karsen's largest purchase order was 10,000 units , worth over $34.59K on June 7, 2017. In total, Perry Karsen has made about 2 transactions over a year of their time at Oncomed Pharmaceuticals Inc. Perry Karsen usually trades in June, with the busiest year in 2017 and 2018.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Perry Karsen's' Mailing Address?

  • Mailing address is C/o Celgene Corporation 86 Morris Avenue Summit NJ 07901 NJ

Oncomed Pharmaceuticals Inc Executive Compensation

Name
Year
Salary
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Total
John A. Lewicki, Ph.D., 2017 $419,777 $192,925 $967,675 $167,911 $1,748,288
John A. Lewicki, Ph.D., 2016 $407,550 $141,750 - $146,718 $696,018
Paul Hastings, 2017 $551,127 $169,650 $1,857,110 $60,624 $2,638,511
Paul Hastings, 2016 $535,075 $158,760 - $264,862 $958,697
Sunil Patel, 2017 $406,117 $183,600 $939,700 $167,780 $1,697,197
Austin Gurney, Ph.D., 2017 $365,612 $154,536 $804,964 $116,996 $1,442,108
Alicia Hager, J.D., Ph.D., 2017 $347,619 $154,536 $804,964 $125,143 $1,432,262
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1302573/000156459018009577/omed-def14a_20180622.htm

What are Oncomed Pharmaceuticals Inc's Past Insider Trades?

Oncomed Pharmaceuticals Inc's most recent insider trade came on December 26, 2018 by Austin Gurney who sold 11,117 units worth $6.67K . In the last 5 years, insiders at Oncomed Pharmaceuticals Inc have sold an estimated value of $14.76M and bought an estimated value of $23.88M worth of shares. Insider trading is most common in June, with the busiest year in 2015. The most active traders at the company are Austin Gurney, See Remarks,  John A Lewicki, President and CEO,  and Alicia J Hager, SVP and General Counsel .

OncoMed Pharmaceuticals Inc Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1